

Tadaaki Yamada

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5719650/tadaaki-yamada-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

2,646
citations

30
h-index

48
g-index

156
ext. papers

3,256
ext. citations

5.6
avg. IF

4.67
L-index

#	Paper	IF	Citations
129	Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Clinical Cancer Research</i> , 2009 , 15, 6630-8	12.9	210
128	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 2011-7	8.9	176
127	EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. <i>Cancer Research</i> , 2013 , 73, 2428-34	10.1	126
126	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019 , 10, 259	17.4	116
125	Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. <i>Clinical Cancer Research</i> , 2012 , 18, 3592-602	12.9	93
124	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2260-9	12.9	89
123	Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 174-83	12.9	85
122	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2149-57	6.1	73
121	Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 1663-71	12.9	71
120	Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. <i>Cancer Science</i> , 2012 , 103, 1189-94	6.9	55
119	Histone Deacetylase 3 Inhibition Overcomes Deletion Polymorphism-Mediated Osimertinib Resistance in Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 3139-3149	12.9	52
118	E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. <i>Clinical Cancer Research</i> , 2009 , 15, 7229-37	12.9	50
117	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	49
116	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. <i>Oncotarget</i> , 2016 , 7, 3847-56	3.3	49
115	Tumor Neovascularization and Developments in Therapeutics. <i>Cancers</i> , 2019 , 11,	6.6	46
114	Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injury. <i>Respiratory Medicine</i> , 2007 , 101, 800-7	4.6	46
113	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	45

112	Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. <i>American Journal of Pathology</i> , 2012 , 181, 1034-43	5.8	45
111	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of Mutation Status. <i>Cancer Research</i> , 2019 , 79, 1658-1670	10.1	44
110	The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 3619-30	12.9	43
109	Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. <i>American Journal of Pathology</i> , 2011 , 179, 1483-93	5.8	42
108	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. <i>Cancer Medicine</i> , 2019 , 8, 1521-1529	4.8	41
107	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. <i>Oncotarget</i> , 2014 , 5, 4920-8	3.3	40
106	Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. <i>PLoS ONE</i> , 2013 , 8, e84700	3.7	38
105	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2244-2256	12.9	36
104	Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of -mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 506-515	6.1	35
103	Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 272-80	8.9	35
102	Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 775-83	8.9	34
101	Notch3-dependent β -catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. <i>Nature Communications</i> , 2018 , 9, 3198	17.4	33
100	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020 , 11, 4607	17.4	31
99	Thioredoxin-1 protects against hyperoxia-induced apoptosis in cells of the alveolar walls. <i>Pulmonary Pharmacology and Therapeutics</i> , 2007 , 20, 650-9	3.5	29
98	Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1078-85	8.9	28
97	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	26
96	The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. <i>International Journal of Cancer</i> , 2013 , 133, 505-13	7.5	25
95	mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. <i>PLoS ONE</i> , 2013 , 8, e62104	3.7	25

94	Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. <i>Cancer Science</i> , 2011 , 102, 2157-63	6.9	24
93	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 847-853	4.4	24
92	Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. <i>Cancer Letters</i> , 2008 , 265, 55-66	9.9	22
91	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. <i>Cancer Science</i> , 2017 , 108, 53-60	6.9	20
90	Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. <i>Oncogene</i> , 2013 , 32, 4427-35	9.2	20
89	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring Mutations. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 17-25	6.1	19
88	Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2. <i>Cancer Science</i> , 2008 , 99, 1603-10	6.9	19
87	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. <i>Cancer Research</i> , 2017 , 77, 153-163	10.1	18
86	Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 119-26	6.1	18
85	Foretinib Overcomes Entrectinib Resistance Associated with the G667C Mutation in Fusion-Positive Tumor Cells in a Brain Metastasis Model. <i>Clinical Cancer Research</i> , 2018 , 24, 2357-2369	12.9	17
84	Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. <i>Cancer Science</i> , 2013 , 104, 1640-6	6.9	16
83	Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. <i>Cancers</i> , 2019 , 11,	6.6	15
82	Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. <i>Cancer Science</i> , 2017 , 108, 1378-1385	6.9	13
81	E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1218-28	6.1	13
80	A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. <i>Oncology Research</i> , 2009 , 17, 581-91	4.8	13
79	The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1061-1076	8.9	12
78	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. <i>Cancer Research</i> , 2015 , 75, 4188-97	10.1	12
77	A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. <i>European Journal of Dermatology</i> , 2017 , 27, 193-194	0.8	10

76	Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer. <i>International Journal of Cancer</i> , 2016 , 138, 1281-9	7.5	10
75	Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 227-234	4.4	10
74	Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. <i>Oncology Reports</i> , 2014 , 31, 1109-15	3.5	10
73	Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. <i>Cancer Science</i> , 2017 , 108, 696-703	6.9	9
72	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. <i>Lung Cancer</i> , 2019 , 137, 108-112	5.9	9
71	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 947-956	6.1	9
70	Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer. <i>Pancreas</i> , 2014 , 43, 1093-100	2.6	9
69	A novel potent inhibitor of inducible nitric oxide synthase, ONO-1714, reduces hyperoxic lung injury in mice. <i>Respiratory Medicine</i> , 2007 , 101, 793-9	4.6	9
68	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019 , 8, 450-460	4.4	8
67	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. <i>Oncologist</i> , 2019 , 24, 593-e170	5.7	8
66	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. <i>Cancers</i> , 2019 , 11,	6.6	8
65	Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58, 735-41	3.5	8
64	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 526-532	3.2	7
63	Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. <i>Cancers</i> , 2019 , 11,	6.6	7
62	Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. <i>Cancer Science</i> , 2015 , 106, 102-7	6.9	7
61	Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920927841	5.4	6
60	Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. <i>Scientific Reports</i> , 2020 , 10, 17495	4.9	6
59	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. <i>BMC Pulmonary Medicine</i> , 2018 , 18, 193	3.5	6

58	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2021 , 161, 26-33	5.9	6
57	Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). <i>Clinical Lung Cancer</i> , 2019 , 20, e402-e406	4.9	5
56	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
55	Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. <i>Investigational New Drugs</i> , 2018 , 36, 903-910	4.3	5
54	Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment. <i>Medicine (United States)</i> , 2018 , 97, e11081	1.8	5
53	Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis. <i>Medicine (United States)</i> , 2018 , 97, e11084	1.8	5
52	Antiangiogenic therapies for malignant pleural mesothelioma. <i>Frontiers in Bioscience - Landmark</i> , 2011 , 16, 740-8	2.8	5
51	Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 468-72	4.2	5
50	Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. <i>International Journal of Clinical Oncology</i> , 2010 , 15, 638-41	4.2	5
49	Plasma membrane anchored nanosensor for quantifying endogenous production of HO in living cells. <i>Biosensors and Bioelectronics</i> , 2021 , 179, 113077	11.8	5
48	TGF- β -dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. <i>Communications Biology</i> , 2021 , 4, 782	6.7	5
47	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. <i>Onc Immunology</i> , 2021 , 10, 1950411	7.2	5
46	Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. <i>Respiratory Medicine Case Reports</i> , 2018 , 25, 261-263	1.2	5
45	Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2019 , 37, 291-296	4.3	4
44	Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. <i>Clinical Cancer Research</i> , 2012 , 18, PR7-PR7	12.9	4
43	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021 , 11, 663612	5.3	4
42	Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. <i>Thoracic Cancer</i> , 2019 , 10, 557-563	3.2	3
41	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019 , 24, 1033-e617	5.7	3

40	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
39	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.. <i>Diagnostics</i> , 2022 , 12,	3.8	3
38	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021 , 11, 630136	5.3	3
37	Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study). <i>Translational Lung Cancer Research</i> , 2019 , 8, 1086-1090	4.4	3
36	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. <i>Cancer Letters</i> , 2021 , 522, 119-128	8.9	3
35	The role of percutaneous needle biopsy in differentiation of renal tumors. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40, 1081-6	2.8	2
34	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.. <i>Cancer Medicine</i> , 2022 ,	4.8	2
33	HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. <i>Current Signal Transduction Therapy</i> , 2011 , 6, 228-233	0.8	2
32	The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2019 , 59, 128-136	0.1	2
31	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. <i>JOP: Journal of the Pancreas</i> , 2013 , 14, 515-20	1.2	2
30	TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021 , 29, 313-320	1.9	2
29	Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020 , 25, 208-e417	5.7	2
28	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. <i>Medical Oncology</i> , 2020 , 37, 111	3.7	2
27	Androgen replacement therapy for cancer-related symptoms in male: result of prospective randomized trial (ARTFORM study). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 831-842	10.3	2
26	A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019 , 24, 459-e131	5.7	2
25	Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis. <i>Allergology International</i> , 2020 , 69, 465-467	4.4	1
24	In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. <i>Cancer Medicine</i> , 2017 , 6, 2972-2983	4.8	1
23	Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study). <i>Journal of Medical Investigation</i> , 2017 , 64, 202-204	1.2	1

22	Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy. <i>Internal Medicine</i> , 2009 , 48, 1651-6	1.1	1
21	The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. <i>Internal Medicine</i> , 2020 , 59, 1605-1610	1.1	1
20	Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2021 , 13, 173	3.2	1
19	Histone deacetylase inhibitor OBP-801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1-dependent apoptosis. <i>International Journal of Oncology</i> , 2020 , 56, 848-856	4.4	1
18	Association of immune checkpoint inhibitors with respiratory infections: A review. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102109	14.4	1
17	Advanced G-CSF-producing non-small cell lung cancer-not otherwise specified, with favourable response to pembrolizumab monotherapy. <i>Respirology Case Reports</i> , 2020 , 8, e00625	0.9	1
16	Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab. <i>Internal Medicine</i> , 2021 , 60, 3585-3588	1.1	1
15	Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma. <i>Respirology Case Reports</i> , 2018 , 6, e00372	0.9	1
14	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2018 , 18, 1241	4.8	1
13	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated -mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3582-3593	4.4	1
12	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.. <i>Npj Precision Oncology</i> , 2022 , 6, 5	9.8	0
11	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	0
10	Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. <i>Translational Lung Cancer Research</i> , 2021 , 10, 193-201	4.4	0
9	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	0
8	A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.. <i>Translational Lung Cancer Research</i> , 2022 , 11, 238-249	4.4	0
7	A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.. <i>International Immunopharmacology</i> , 2022 , 108, 108775	5.8	0
6	Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801. <i>Oncologist</i> , 2020 , 25, e1146-e1157	5.7	
5	Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study). <i>Translational Lung Cancer Research</i> , 2019 , 8, 519-523	4.4	

- | | | |
|---|---|------|
| 4 | Two cases of primary malignant melanoma of the esophagus. <i>Skin Cancer</i> , 2017 , 32, 6-11 | 0 |
| 3 | Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. <i>Clinical Cancer Research</i> , 2012 , 18, B21-B21 | 12.9 |
| 2 | Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients. <i>Nephron</i> , 2020 , 144, 525-536 | 3.3 |
| 1 | An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. <i>Medicine (United States)</i> , 2018 , 97, e12660 | 1.8 |